These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38687638)

  • 1. Discovery of LLC0424 as a Potent and Selective
    Liu L; Parolia A; Liu Y; Hou C; He T; Qiao Y; Eyunni S; Luo J; Li C; Wang Y; Zhou F; Huang W; Ren X; Wang Z; Chinnaiyan AM; Ding K
    J Med Chem; 2024 May; 67(9):6938-6951. PubMed ID: 38687638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos.
    Meng F; Xu C; Park KS; Kaniskan HÜ; Wang GG; Jin J
    J Med Chem; 2022 Aug; 65(15):10611-10625. PubMed ID: 35895319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
    Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
    Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2.
    Wei J; Shi Q; Li B; Yang H; Liu L; Zhou R; Feng Z; Yang Z; Zhan J; Xiong XF; Huang X; Wang Y
    J Med Chem; 2024 Sep; 67(18):16056-16071. PubMed ID: 39230932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2.
    Hanley RP; Nie DY; Tabor JR; Li F; Sobh A; Xu C; Barker NK; Dilworth D; Hajian T; Gibson E; Szewczyk MM; Brown PJ; Barsyte-Lovejoy D; Herring LE; Wang GG; Licht JD; Vedadi M; Arrowsmith CH; James LI
    J Am Chem Soc; 2023 Apr; 145(14):8176-8188. PubMed ID: 36976643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2.
    Ferreira de Freitas R; Liu Y; Szewczyk MM; Mehta N; Li F; McLeod D; Zepeda-Velázquez C; Dilworth D; Hanley RP; Gibson E; Brown PJ; Al-Awar R; James LI; Arrowsmith CH; Barsyte-Lovejoy D; Min J; Vedadi M; Schapira M; Allali-Hassani A
    J Med Chem; 2021 Feb; 64(3):1584-1592. PubMed ID: 33522809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin.
    Sankaran SM; Wilkinson AW; Elias JE; Gozani O
    J Biol Chem; 2016 Apr; 291(16):8465-74. PubMed ID: 26912663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors.
    Yang C; Li B; Feng Z; Li H; Yang H; Yang Z; Liu L; Shi Q; Wang H; Chen ZZ; Huang X; Wang J; Wang Y
    J Med Chem; 2024 Sep; 67(18):16072-16087. PubMed ID: 39008565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of the First-in-Class G9a/GLP PROTAC Degrader.
    Velez J; Han Y; Yim H; Yang P; Deng Z; Park KS; Kabir M; Kaniskan HÜ; Xiong Y; Jin J
    J Med Chem; 2024 Apr; 67(8):6397-6409. PubMed ID: 38602846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader.
    Kabir M; Qin L; Luo K; Xiong Y; Sidi RA; Park KS; Jin J
    J Med Chem; 2024 Apr; 67(8):6880-6892. PubMed ID: 38607318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteosomal degradation of NSD2 by BRCA1 promotes leukemia cell differentiation.
    Park JW; Kang JY; Hahm JY; Kim HJ; Seo SB
    Commun Biol; 2020 Aug; 3(1):462. PubMed ID: 32826945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
    Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
    J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of NSD2-Degraders from Novel and Selective DEL Hits.
    LegaardAndersson J; Christensen J; Kleine-Kohlbrecher D; Vacher Comet I; Fullerton Støier J; Antoku Y; Poljak V; Moretti L; Dolberg J; Jacso T; Jensby Nielsen S; Nørregaard-Madsen M; Franch T; Helin K; Cloos PAC
    Chembiochem; 2023 Dec; 24(24):e202300515. PubMed ID: 37807669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Highly Potent, Selective and Efficacious USP7 Degrader for the Treatment of Acute Lymphoblastic Leukemia.
    Xu M; Fu J; Pei Y; Li M; Kan W; Yan R; Xia C; Ma J; Wang P; Zhang Y; Gao Y; Yang Y; Zhou Y; Li J; Zhou B
    J Med Chem; 2024 Aug; 67(15):13197-13216. PubMed ID: 39028938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
    Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
    J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.
    García-Carpizo V; Sarmentero J; Han B; Graña O; Ruiz-Llorente S; Pisano DG; Serrano M; Brooks HB; Campbell RM; Barrero MJ
    Sci Rep; 2016 Sep; 6():32952. PubMed ID: 27604143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.
    Yang P; Guo L; Duan ZJ; Tepper CG; Xue L; Chen X; Kung HJ; Gao AC; Zou JX; Chen HW
    Mol Cell Biol; 2012 Aug; 32(15):3121-31. PubMed ID: 22645312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
    Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
    Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for histone codebreakers.
    Bedford MT
    J Biol Chem; 2018 Aug; 293(35):13766-13767. PubMed ID: 30171150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activities.
    Zhang X; Wang W; Dong G; Song Y; Zhai X; Sheng C
    Bioorg Med Chem Lett; 2024 Sep; 109():129838. PubMed ID: 38838918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.